Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

A Varicella-Zoster Virus Mutant that is Markedly Impaired for Latent Infection Available for the Development of Shingles Vaccine

Posted Nov 30 2008 4:00pm

Description of Invention:
Reactivation of latent Varicella-Zoster virus (VZV) infection is the cause of shingles, which is prominent in adults over the age of 60 and individuals who have compromised immune systems, due to HIV infection, cancer treatment and/or transplant. Shingles is a worldwide health concern that affects approximately 600,000 Americans each year. The incidence of shingles is also high in Europe, South America, and India; the latter having an estimated two million individuals affected, yearly. Recent research studies show that VZV vaccines have a significant effect on decreasing the incidence of shingles in elderly.

The current technology describes compositions, cells and methods related to the production and use of a mutant VZV and the development of vaccines against the infectious agent. Latent VZV expresses a limited repertoire of viral genes including the following six open reading frames (ORFs): 4, 21, 29, 62, 63, and 66. The present invention describes an ORF29 mutant VZV that demonstrates a weakened ability to establish latency in animal studies. The current technology provides methods for using the mutant in the development of live vaccines and diagnostic tools. A related invention is described in PCT/US05/021788 (publication number WO2006012092).

Applications:
Development of vaccines and diagnostics for prevention of shingles

Development Status:
Pre-clinical studies have been performed to demonstrate the reduced latency of the ORF29 mutant VZV in animals.

Inventors:
Jeffrey I Cohen (NIAID)
Lesley Pesnicak (NIAID)


Patent Status:
HHS, Reference No. E-029-2007/0
PCT, Application No. PCT/US2007/084331 filed 09 Nov 2007
US, Application No. 12/514,011 filed 07 May 2009


Licensing Status:
Available for licensing and commercial development.

Collaborative Research Opportunity:
The NIAID Laboratory of Clinical Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize vaccine strains of VZV vaccine with impaired latency. Please contact Jason Freeman, J.D., at 301/451-5054 or freemanch@mail.nih.gov for more information.


Portfolios:
Infectious Diseases
Infectious Diseases - Diagnostics
Infectious Diseases - Vaccines



For Additional Information Please Contact:
Kevin Chang Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: changke@mail.nih.gov
Phone: 301-435-5018
Fax: 301-402-0220


Ref No: 1501

Updated: 12/2008

Post a comment
Write a comment:

Related Searches